https://orcid.org/0000-0002-4183-9596
References
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):1–9.
- Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181.
- Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167.
- Hagino T, Saeki H, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023.
- Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458.
- Chu H, Shin JU, Park CO, et al. Clinical diversity of atopic dermatitis: a review of 5,000 patients at a single institute. Allergy Asthma Immunol Res. 2017;9(2):158–168.
- Stone SP, Muller SA, Gleich GJ. IgE levels in atopic dermatitis. Arch Dermatol. 1973;108(6):806–811.
- Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15(5):453–460.
- Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561–570.
- Alexis A, de Bruin-Weller M, Weidinger S, et al. Rapidity of improvement in signs/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther. 2022;12(3):771–785.
- Darabi K, Hostetler SG, Bechtel MA, et al. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60(1):125–136.
- Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019;181(1):196–197.
- Chu H, Kim SM, Zhang K, et al. Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front Immunol. 2023;14:1114321.
- Murota H, Yamaga K, Ono E, et al. Sweat in the pathogenesis of atopic dermatitis. Allergol Int. 2018;67(4):455–459.
- Coull NA, West AM, Hodder SG, et al. Body mapping of regional sweat distribution in young and older males. Eur J Appl Physiol. 2021;121(1):109–125.
- Murota H, Yamaga K, Ono E, et al. Why does sweat lead to the development of itch in atopic dermatitis? Exp Dermatol. 2019;28(12):1416–1421.
- Staudinger T, Pipal A, Redl B. Molecular analysis of the prevalent microbiota of human male and female forehead skin compared to forearm skin and the influence of make-up. J Appl Microbiol. 2011;110(6):1381–1389.
- Gao Z, Perez-Perez GI, Chen Y, et al. Quantitation of major human cutaneous bacterial and fungal populations. J Clin Microbiol. 2010;48(10):3575–3581.